CliffBio
biologic

Zemaira

Alpha-1-Proteinase Inhibitor (Human)

Loss of exclusivityApril 2031projected — 12-year biologic exclusivity estimate
CompanyCSL Behring →View the full company profile on CliffBio

Drug detail

Brand nameZemaira
Active ingredientAlpha-1-Proteinase Inhibitor (Human)
Strength5000MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2019
Marketing statusRx

More from CSL Behring

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Zemaira patent cliff — loss of exclusivity April 2031 | CliffBio